Scholarlink

Background <p>The use of natural medicines as adjuvant therapies for fibrotic diseases has recently garnered significant attention. Diallyl disulfide (DADS), a bioactive sulfur compound from garlic, exhibits antioxidant, anti-inflammatory, and immunomodulatory effects, but its impact on colitis-associated intestinal fibrosis is unknown.</p> Methods <p>We administered DADS (80&#xa0;mg/kg orally) to mice with dextran sulfate sodium (DSS)-induced chronic colitis-associated intestinal fibrosis and assessed clinical parameters, histopathological, immunohistochemistry, 16S rDNA—based gut microbiota profiling, and Mendelian randomization analysis.</p> Results <p>DADS treatment ameliorated weight loss, disease activity index (DAI), colon shortening and histological damage, and reduced inflammatory infiltration and collagen deposition. Mechanistically, DADS activated the Nrf2 antioxidant pathway, inhibited TGF-β1/Smad3 fibrogenic signaling, and favorably altered gut microbial diversity and composition.</p> Conclusion <p>By engaging Nrf2, suppressing TGF-β1/Smad3 and modulating the gut microbiota, DADS attenuates colitis-associated intestinal fibrosis, highlight its potential as novel anti-fibrotic adjuvant.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diallyl disulfide attenuates DSS-induced colonic fibrosis in mice by modulating gut microbiota and Nrf2 signaling

  • 期刊论文

  • 发表日期：

    2025年10月2日

查看全文
  • Shuangshuang Hai,
  • Yan Chen,
  • Meiyan Zhang,
  • Weixin Liu,
  • Xiaohong Sun

摘要

Background

The use of natural medicines as adjuvant therapies for fibrotic diseases has recently garnered significant attention. Diallyl disulfide (DADS), a bioactive sulfur compound from garlic, exhibits antioxidant, anti-inflammatory, and immunomodulatory effects, but its impact on colitis-associated intestinal fibrosis is unknown.

Methods

We administered DADS (80 mg/kg orally) to mice with dextran sulfate sodium (DSS)-induced chronic colitis-associated intestinal fibrosis and assessed clinical parameters, histopathological, immunohistochemistry, 16S rDNA—based gut microbiota profiling, and Mendelian randomization analysis.

Results

DADS treatment ameliorated weight loss, disease activity index (DAI), colon shortening and histological damage, and reduced inflammatory infiltration and collagen deposition. Mechanistically, DADS activated the Nrf2 antioxidant pathway, inhibited TGF-β1/Smad3 fibrogenic signaling, and favorably altered gut microbial diversity and composition.

Conclusion

By engaging Nrf2, suppressing TGF-β1/Smad3 and modulating the gut microbiota, DADS attenuates colitis-associated intestinal fibrosis, highlight its potential as novel anti-fibrotic adjuvant.